Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Viridian Therapeutics Inc VRDN

Healthcare Biotechnology
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and... see more

Recent & Breaking News (NDAQ:VRDN)

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm

Newsfile March 14, 2024

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 6, 2024

Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Business Wire March 5, 2024

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Business Wire February 27, 2024

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Viridian Therapeutics, Inc. (VRDN)

Newsfile February 26, 2024

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Viridian Therapeutics, Inc. (VRDN)

Newsfile February 22, 2024

Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer

Business Wire February 16, 2024

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire February 6, 2024

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. and Encourages Investors to Contact the Firm - VRDN

Accesswire January 30, 2024

Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock

Business Wire January 17, 2024

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Business Wire January 17, 2024

Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference

Business Wire January 8, 2024

Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Business Wire January 4, 2024

Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease

Business Wire December 18, 2023

Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference

Business Wire November 21, 2023

Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Business Wire November 13, 2023

Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference

Business Wire November 8, 2023

Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology

Business Wire November 3, 2023

Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing

Business Wire October 30, 2023

Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease

Business Wire October 26, 2023